Crazy idea - Forget all about Brilacidin for the
Post# of 72440
Kevetrin has been dead in the water for years due to lack of funds to finish tox tests on the oral version (pill). From news a number of years ago about 1/2 of the tests had been finished.
Realistically, how much can the balance cost? When one realizes K showed very promising results for lymphoma (think that's what it was) at the U of Bologna in Italy and in conjunction with some other cancer treatment in the USA provided the only known remission in renal cancer and the Cancer Foundation makes many, many billions a year to fund cancer research it is beyond me why K hasn't moved forward.
One would think some BP would take a flyer to get this pill finished and authorized to be used in a multitude of trials as a complementary aid to other current treatments such as was done with the renal cancer drug.
I am just trying to consider ways we could get things moving forward instead of seeming to be in a hover mode.
The potential for K in cancer is so large let's get some deal made that would profit IPIX and the BP. Win-Win.